Title Details

Major purpose

To provide a single comprehensive source of information, including differing viewpoints, concerning HCM as well as cardiovascular disease in athletes - - - for clinical and research cardiologists, primary care physicians, and basic scientists, and written and assembled by all the experts in the field.

3 features

1. The book literally includes the contributions of all experts in the field and therefore can be regarded as truly comprehensive, taking into account sometimes diverse viewpoints regarding this heterogeneous disease (i.e., HCM) and related issues in athletes.

2. There is no other available source that comes remotely close...so it is a novel undertaking.

3. Because there is so much misunderstanding regarding the aforementioned issues in the physician community...and because these are not clinical problems necessarily encountered on a daily basis by most practicing physicians...this book becomes a particularly important source to interested parties - - - i.e., information they may not be able to assemble easily in any other way.

Recent advances of note

1. Use of implantable defibrillator in HCM for prevention of sudden death in young people.

2. Introduction of catheter-based alcohol septal ablation to reduce obstruction and symptoms as a treatment alternative to surgery for some HCM patients.

3. Definition of the genetic basis for HCM and its role in clinical diagnosis and risk stratification.

4. Development of more precise strategies for assessing the level of risk for sudden death among all patients with HCM.

5. More precise definition of the relatively high frequency with which HCM occurs in the general population.

Special emphasis

All of the above, plus: the septal myectomy operation remains the gold standard for the severely symptomatic patient with obstruction, refractory to medications.

Dedication and Acknowledgments.

List of Contributors.

1. Phenotypic Expression and Clinical Course of Hypertrophic Cardiomyopathy.

Barry J. Maron, MD2. Genetic Mutations that Remodel the Heart Carolyn Y. Ho, MD and Christine E. Seidman, MD.

3. Genetic Basis and Genotype-Phenotype Relationships in Familial Hypertrophic Cardiomyopathy.

Albert A. Hagège, MD, PhD, Ketty Schwartz, PhD, Michel Desnos, MD, and Lucie Carrier, PhD.

4. Historical Perspective, Mechanism, and Clinical Significance of Left Ventricular Outflow Tract Obstruction in Hypertrophic CardiomyopathyMartin S. Maron, MD, Iacopo Olivotto, MD, and Barry J. Maron, MD.

5. Hypertrophic Cardiomyopathy with Latent (Provocable) Obstruction: Pathophysiology and Management.

E. Douglas Wigle, MD, Maria Eriksson, MD, PhD, Paul Rakowski, David Focsaneanu, Cairrine Sloggett, RN, Anna Woo, MD, and Harry Rakowski, MD.

6. Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Iacopo Olivotto, MD, Barry J. Maron, MD, and Franco Cecchi, MD.

7. Other Modes of Disability or Death Including Stroke, and Treatment Strategies in Hypertrophic CardiomyopathyFranco Cecchi, MD, Iacopo Olivotto, MD, and Barry J. Maron, MD.

8. Disturbed Vascular Control in Hypertrophic Cardiomyopathy: Mechanisms and Clinical Significance.

Ross Campbell, BSc,Jayne A. Morris-Thurgood, PhD, and Michael P. Frenneaux, FRCP, FRACP.

9. Clinical Significance of Diastolic Dysfunction and the Effect of Therapeutic Interventions.

Sandro Betocchi, MD and Raffaella Lombardi, MD.

10. Value of Exercise Testing in Assessing Clinical State and Prognosis in Hypertrophic Cardiomyopathy.

Sanjay Sharma, MRCP, MD.

11. Pathophysiology and Significance of Myocardial Ischemia in Hypertrophic Cardiomyopathy.

Rajesh Thaman MBBS, MRCP, Bhavesh Sachdev MBBS, MRCP, and Perry M. Elliott MBBS, MD, MRCP.

12. Hypertrophic Cardiomyopathy in Japan: Clinical, Morphologic and Genetic Expression.

Yoshinori Doi, MD, PhD, Hiroaki Kitaoka, MD, Nobuhiko Hitomi, MD, Naohito Yamasaki, MD, Yoshihisa Matsumura, MD, Takashi Furuno, MD, and Barry J. Maron, MD.

13. Prevalence, Prevention and Treatment of Infective Endocarditis in Hypertrophic CardiomyopathyPaolo Spirito, MD, Marco Piccininno, MD, and Camillo Autore, MD.

14. Pharmacologic Treatment of Symptomatic Hypertrophic CardiomyopathyMark V. Sherrid, MD and Ivan Barac, MD.

15. Obstructive Hypertrophic Cardiomyopathy: Results of Septal Myectomy Gordon K. Danielson, MD and Joseph A. Dearani, MD.

16. US Perspectives on the Role of Dual-Chamber Pacing in Patients with Hypertrophic CardiomyopathyPaul Sorajja, MD, Steve R. Ommen, MD, and Rick A. Nishimura, MD.

17. Dual-Chamber Pacing for Hypertrophic Obstructive Cardiomyopathy Xavier Jeanrenaud, MD, and Lukas Kappenberger, MD.

18. Alcohol Septal Ablation Hubert Seggewiss, MD Prof. Angelos Rigopoulos, MD, Lothar Faber, MD, and Peer Ziemssen, MD.

19. Alcohol Septal Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Seven-Year Experience.

Horst Kuhn, MD, Thorsten Lawrenz, MD, Frank Lieder, MD, Frank H. Gietzen, MD, Ludger Obergassel, MD, Claudia Strunk-Muller, MD, Berit Stolle, MD, and Christian H. Leuner, MD.

20. Role of Septal Ablation in a Surgical CenterHarry M. Lever, MD.

21. Molecular and Clinical Tools for Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy.

Asifa Quraishi MB, MRCP, Mohammad S. Hamid MB, MRCP, and William J. McKenna MD, FRCP.

21A. In Memorium: Asifa Quraishi.

22. Risk Stratification For Sudden Death in Hypertrophic Cardiomyopathy: Extreme Left Ventricular Hyptertrophy as a New Indicator of Risk.

Paolo Spirito, MD and Barry J. Maron, MD.

23. Implantable Defibrillator for Prevention of Sudden Death in Hypertrophic Cardiomyopathy.

Barry J. Maron, MD, Win-Kuang Shen, MD, and Paolo Spirito, MD.

24. Hypertrophic Cardiomyopathy and Other Causes of Sudden Death in the Trained Athlete: An Electrophysiologist Perspective on the Management of Benign and Not So Benign Arrhythmias.

N.A. Mark Estes III, MD, Paul J. Wang, MD, Munther K. Homoud, MD, and Mark S. Link, MD.

25. The Athlete’s Heart, the Athlete’s ECG, and Differential Diagnosis with HCM and Other Cardiomyopathies.

Antonio Pelliccia, MD and Barry J. Maron, MD.

26. Importance of Congenital Coronary Artery AnomaliesCristina Basso, MD, PhD, Domenico Corrado, MD, and Gaetano Thiene, MD.

27. Arrhythmogenic Right Ventricular Cardiomyopathy and Hypertrophic Cardiomyopathy: Identification with the Italian Preparticipation Athlete Screening Program.

Domenico Corrado, MD, Cristina Basso, MD, PhD, Maurizio Schiavon, MD, and Gaetano Thiene, MD.

28. Cardiovascular Causes of Sudden Death, Preparticipation Screening, and Criteria for Disqualification in Young AthletesBarry J. Maron, MD.

29.Sudden Death Due to Chest Blows (Commotio Cordis).

Mark S. Link, MD, N. A. Mark Estes III, MD, and Barry J. Maron, MD.

30. Naturally Occurring Animal Models of Cardiovascular Disease Causing Premature Death.

Philip R. Fox, DVM.

31. The Role of the Internet and Patient Support Groups for Those Living with Hypertrophic Cardiomyopathy.

Lisa Salberg.

AfterwordRobert Jon Pensack, MD.

Index